SARS-CoV-2-Triggered Hemophagocytic Lymphohistiocytosis with
Complications of Posterior Reversible Encephalopathy Syndrome
Ross M. Perry, M.D. a* | Scott D. Casey,
M.D., M.S. b | Alex Q. Lee, M.D.a | Sylvia P. Bowditch, M.D.c | Mary A. Rasmussen, M.D.c | Viyeka Sethi, M.D. d| Arun R. Panigrahi, M.D. e
aUniversity of California, Davis, School of Medicine,
Sacramento, California, USA; bDepartment of Emergency
Medicine, University of California, Davis, Sacramento, California,
U.S.A.; cDepartment of Pediatrics, University of
California, Davis, Sacramento, California, U.S.A;dDepartment of Pediatric Critical Care Medicine,
University of California, Davis, Sacramento, California, U.S.A;eDepartment of Pediatric Hematology & Oncology,
University of California, Davis, Sacramento, California, U.S.A
*Correspondence to:
Ross Perry, M.D., 14 Rock Lane, Berkeley, CA, 94708, Phone: (707)
331-4626, Fax: (510) 752-1571, E-mail:
rossmperry@gmail.com
Main Text Word Count: 850
Tables: 1; Figures: 1
Short Title: SARS-CoV-2-Triggered HLH Complicated by PRES
Keywords: SARS-CoV-2, HLH, PRES, MIS-C, corticosteroids, anakinra